Jardiance (Empagliflozin) for Children Under 12: School and Activity Guide for Parents

What Parents Need to Know First

Jardiance (empagliflozin) belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. In children, it lowers blood sugar by causing the kidneys to excrete glucose in the urine rather than reabsorbing it. The FDA approved empagliflozin for type 1 diabetes in patients aged 10 and older in November 2023, but pediatric use in children younger than 10 remains investigational.

If your daughter is under 10 and her endocrinologist has prescribed empagliflozin off-label, you are working with limited direct evidence. The adult type 1 diabetes data from the EASE-3 trial, published in the New England Journal of Medicine in 2019, showed a 0.28% reduction in HbA1c and a meaningful reduction in time above range, but DKA rates were higher in the 10 mg arm. Pediatric-specific trial results in the under-12 age group are still emerging. Your child's team is extrapolating from adult and adolescent data. That is honest, and it matters for how you plan her school day.

How Empagliflozin Works Differently in Younger Children

The Kidneys Filter More Glucose

Children under 12 have higher glomerular filtration rates relative to body size than adults. This means empagliflozin may cause more glucose to spill into the urine per kilogram of body weight, which can amplify both the glucose-lowering effect and the risk of dehydration during activity.

Smaller Bodies Lose Fluid Faster

A child weighing 30 kg loses a meaningfully larger share of her fluid volume through glucosuria compared with a 70 kg adult on the same 2.5 mg dose. During a 60-minute recess or a PE class on a warm day, this matters. She may not feel thirsty until she is already mildly dehydrated.

Prepubertal Girls and Genital Yeast Infections

SGLT2 inhibitors increase urinary glucose, which creates a growth environment for Candida species. In adult women, genital mycotic infections occur in approximately 10% of those taking empagliflozin versus 1.5% on placebo. Prepubertal girls have lower estrogen levels, which means different vaginal flora, but the glucosuria risk still applies. Watch for vulvar itching, redness, or unusual discharge. Tell the school nurse to flag these symptoms.

School-Day Safety: A Room-by-Room Plan

Managing empagliflozin safely at school requires coordination between you, the endocrinology team, the school nurse, and the classroom teacher. Do not assume the school has seen this drug before. Many school nurses have not.

The School Nurse Conversation

Bring a one-page medication action plan that covers three scenarios: a low blood sugar episode, a suspected DKA episode, and a sick day. The nurse needs to know that DKA on empagliflozin can occur with a blood glucose reading that looks nearly normal. This is called euglycemic DKA, and it is the most dangerous misunderstanding a school can have.

Key items to put in writing for the nurse:

• Blood glucose does not have to be above 250 mg/dL for DKA to be present on this medication
• Symptoms to watch: nausea, vomiting, abdominal pain, rapid breathing, fruity-smelling breath, fatigue
• If any two of those symptoms appear, call 911 and the parents simultaneously. Do not wait for a glucose reading to confirm.
• Ketone testing strips (blood or urine) should be available in the nurse's office

Classroom and Lunch Considerations

The medication is taken once daily in the morning, ideally before school. Your daughter should not take a missed dose at school. If she forgot her morning dose, skip it that day and resume the next morning. Do not double dose.

Lunch is not just a meal on this medication. Because glucosuria continues throughout the day, she needs adequate carbohydrate intake at lunch to avoid hypoglycemia, particularly if she is also using insulin. Coordinate with her dietitian on a target carbohydrate range. A 2022 review in Diabetes Care noted that insulin dose reductions of 10-20% are typically needed when adding an SGLT2 inhibitor to a type 1 diabetes regimen, to reduce hypoglycemia risk.

Sick Days at School

This is the most important rule to communicate to every adult who cares for your child at school: if she vomits even once, empagliflozin must be held and you must be contacted immediately. Vomiting on an SGLT2 inhibitor can tip a child into DKA within hours.

Write "HOLD JARDIANCE IF VOMITING" in large text on her medication action plan. Schools handle sick-day protocols for insulin. SGLT2 inhibitor sick-day rules are less familiar, and this gap is where errors happen.

Physical Activity, Sports, and After-School Programs

Below is a practical framework for managing empagliflozin around your child's physical activity. No published pediatric trial has specifically studied SGLT2 inhibitor management during exercise in children under 12. This framework is adapted from adult exercise physiology data and expert consensus statements from the American Diabetes Association, with adjustments for body size and developmental stage.

Before Activity: Hydration First

Your child should drink 200-300 mL of water (roughly one standard school water bottle) in the 30 minutes before any activity lasting more than 20 minutes. This is not optional. Glucosuria from empagliflozin plus sweat loss from exercise can create a fluid deficit fast enough to cause dizziness or fatigue that a child may not know how to describe.

During Activity: Know the DKA Prodrome in Kids

Children often cannot articulate early DKA symptoms. Coaches and activity leaders should know that the following signs in a child on Jardiance warrant stopping the activity and calling a parent:

• Complaining of stomachache during exercise (not just stitch)
• Looking pale or "zoned out" mid-activity
• Unusual fatigue that does not improve with a 5-minute rest
• Any vomiting

A quick blood ketone check (target below 0.6 mmol/L) takes 10 seconds with a handheld meter. If your child plays a competitive sport, consider asking the team to have a ketone meter in the first-aid kit.

After Activity: Re-Check and Refuel

Blood glucose and ketones should both be checked within 30 minutes of finishing strenuous activity. The ADA Standards of Care 2024 recommend checking ketones whenever blood glucose drops below 70 mg/dL in anyone using an SGLT2 inhibitor with insulin, because hypoglycemia and elevated ketones can coexist in this combination. A post-activity snack with 15-20 g of carbohydrate is a reasonable default; your endocrinologist will adjust based on continuous glucose monitor trends.

Swimming and Water Sports

Swimming deserves special attention. Chlorinated water exposure does not affect the medication, but prolonged water activity tends to suppress the perception of thirst. Encourage your child to take a water break every 20-30 minutes. Also confirm that her continuous glucose monitor (CGM) adhesive is waterproof; a detached sensor during water activity leaves her without real-time glucose data.

High-Altitude and Cold-Weather Activities

These are less studied. Cold weather increases caloric expenditure. High altitude can cause altered breathing patterns that may mimic early Kussmaul respirations (the deep, labored breathing of DKA). If your child is going on a ski trip or a high-altitude camp, discuss whether to hold empagliflozin for that period with her endocrinologist. The medication can be paused for short periods without loss of long-term benefit.

Fluid, Nutrition, and the School Lunch Table

Because empagliflozin works by excreting glucose continuously in the urine, your daughter's nutritional needs at school are slightly different from those of a child managing type 1 diabetes with insulin alone.

Hydration Targets

The European Society for Paediatric Endocrinology consensus on SGLT2 inhibitors in children recommends ensuring adequate fluid intake throughout the day, with a minimum of 1.2 liters for a 30 kg child and 1.5 liters for a 40 kg child on school days. Pack a labeled water bottle and ask the teacher to allow unrestricted bathroom and water access. Children on SGLT2 inhibitors urinate more frequently. Restricting bathroom access is a safety issue, not a convenience issue. Put that in writing in the 504 plan or IEP if your school requires formal accommodation.

What Goes in the Lunchbox

Avoid packing a lunch that is predominantly low-carbohydrate on days when your daughter has PE or sports after school. The glucose-lowering effect of empagliflozin is additive with exercise-induced glucose uptake. A lunch with fewer than 20 g of carbohydrate before afternoon activity can lead to post-exercise hypoglycemia even in a child whose morning glucose looked stable.

Good targets for a school-day lunch on empagliflozin: 30-45 g carbohydrate, adequate protein (15-20 g), and a piece of fruit or a small carton of milk for the mid-afternoon snack slot.

Girls-Specific Considerations at Every Life Stage

Empagliflozin is most commonly used in children with type 1 diabetes, and type 1 diabetes affects girls and boys nearly equally. But girls have sex-specific risks that need explicit attention.

Urinary Tract Infections

Girls are anatomically more prone to UTIs at any age. SGLT2 inhibitors increase urinary glucose, which is a bacterial growth medium. In the EMPA-REG OUTCOME trial, UTI rates were approximately 18% in women versus 9% in men taking empagliflozin. While this trial studied adults, the anatomical risk in girls is present from birth. Signs of UTI in a younger child can be subtle: increased accidents, crying when urinating, frequent trips to the bathroom, or a new complaint of lower abdominal pain.

Tell the school nurse that UTI symptoms should be reported to parents the same day, not at pick-up as an afterthought. A UTI that goes untreated for 24 hours in a child on an SGLT2 inhibitor can escalate to pyelonephritis quickly.

Vulvovaginal Hygiene at School

Practical hygiene matters more on this medication. Because glucose is present in the urine, residual moisture in the genital area can encourage yeast and bacterial overgrowth. Encourage front-to-back wiping, cotton underwear, and a change of underwear after swimming or sweaty activity. These are small steps, but they reduce infection risk meaningfully.

Approaching Puberty

As your daughter approaches menarche, her hormonal environment will change. Estrogen shifts vaginal pH and flora, which alters the yeast infection risk profile. She will also need updated conversations about contraception if she becomes sexually active, because empagliflozin is contraindicated in pregnancy (see the section below). Her endocrinologist should revisit the risk-benefit assessment of continuing empagliflozin through puberty with updated guidance at each annual visit.

Pregnancy, Lactation, and Contraception: Required Reading

This section applies most directly to adolescent girls who are or may become sexually active, but parents of younger girls should read it now so the conversation is not rushed later.

Empagliflozin is contraindicated during the second and third trimesters of pregnancy. The FDA labeling notes that SGLT2 inhibitors cause adverse fetal renal effects, including oligohydramnios, fetal renal dysfunction, and skeletal abnormalities in animal studies. The FDA drug label for empagliflozin explicitly states it should be discontinued when pregnancy is detected. Human data in pregnancy are limited; what exists comes from case reports and registry data, not controlled trials. This is an evidence gap, not reassurance.

Any adolescent girl of reproductive potential taking empagliflozin must use effective contraception. The ACOG recommends long-acting reversible contraception (LARC) as first-line for adolescents with chronic conditions that require teratogenic medications, because adherence with daily oral contraceptives is lower in teenagers.

Regarding lactation: empagliflozin is present in rat milk, and potential effects on the developing kidneys of a nursing infant are unknown. The FDA labeling advises against use during breastfeeding. This is relevant for teenage mothers who may be nursing.

If your daughter is currently under 12, this information feels distant. But type 1 diabetes management plans need to be updated with each life stage transition, and empagliflozin's reproductive risks should be built into the plan before she reaches menarche, not after.

When to Hold Empagliflozin: A Clear Decision Tree for School Staff

School staff need simple, unambiguous instructions. Here is a summary to include verbatim in the medication action plan you leave with the school nurse:

HOLD the next dose and call parents immediately if your child:

1. Vomits, even once
2. Has diarrhea more than twice in a morning
3. Refuses to drink fluids for more than 2 hours
4. Has a fever above 38.5°C (101.3°F) and cannot eat
5. Reports nausea, stomach pain, or unusual fatigue during the school day

Call 911 AND the parents simultaneously if your child:

1. Has any two of the following: nausea, vomiting, stomach pain, rapid or labored breathing, confusion, fruity breath
2. Has blood ketones above 1.0 mmol/L on the school's meter
3. Loses consciousness or has a seizure

The distinction between "call parents" and "call 911" must be explicit. Schools are accustomed to calling parents first for anything diabetes-related. With SGLT2 inhibitor-associated DKA, the sequence can matter clinically.

Who This Is Right For and Who Should Not Use It at School Age

Children Who May Benefit

• Girls and boys aged 10 and older with type 1 diabetes who are not meeting glycemic targets on optimized insulin therapy, as described in the 2024 ADA Standards of Care
• Children who experience significant time above range despite good insulin adherence
• Children who also have obesity or insulin resistance alongside type 1 diabetes, where the weight-neutral to modestly weight-reducing effect of SGLT2 inhibition may add benefit

Children and Families for Whom This Is a Higher-Risk Choice

• Any child whose family or school cannot reliably implement sick-day rules or ketone monitoring
• Children who participate in high-intensity or prolonged daily sports without consistent adult supervision
• Children under 10, where prescribing is off-label and parental consent should include explicit discussion of the evidence gap
• Adolescent girls who are sexually active without reliable contraception
• Any child with recurrent UTIs, as empagliflozin will increase the frequency

Talking to the Endocrinologist: Questions to Bring to the Next Appointment

Bring these specific questions to your child's next visit:

1. What is our target blood ketone threshold for holding the dose at home versus going to the emergency department?
2. Should my daughter's insulin-to-carbohydrate ratio be adjusted now that she is on empagliflozin?
3. Does her school need a formal 504 plan to allow unrestricted bathroom access and water breaks?
4. At what point in her development do we revisit whether this medication remains the right choice?
5. What CGM alarm settings should we use to catch euglycemic DKA early?

These questions are specific enough that they will generate actionable answers rather than general reassurance. Write the answers down in the appointment. Empagliflozin management in a young child requires living documentation, not a one-time conversation.